Volume 20, Issue 1 pp. 146-150
Case Report

Sequential renal and bone marrow transplants in a child with Fanconi anemia

Carol L. Vincent

Carol L. Vincent

Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA

Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

Search for more papers by this author
William A. Primack

William A. Primack

Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA

Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

Division of Nephrology, University of North Carolina, Chapel Hill, NC, USA

Search for more papers by this author
John Hipps

John Hipps

Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA

Division of Pediatric Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA

Search for more papers by this author
Kimberly A. Kasow

Corresponding Author

Kimberly A. Kasow

Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA

Division of Pediatric Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA

Kimberly A. Kasow, University of North Carolina, 1108 Physician Office Building, 170 Manning Drive, CB#7236, Chapel Hill, NC 27599-7236, USA

Tel.: +1 919 966 1178

Fax: +1 919 966 7629

E-mail: [email protected]

Search for more papers by this author
First published: 19 October 2015
Citations: 6

Abstract

FA is an autosomal recessive disorder characterized by small stature and renal abnormalities. FA can lead to progressive bone marrow failure, myelodysplastic syndrome, or acute leukemia. Using a multidisciplinary team approach, we managed a 3-yr-old boy with FA who simultaneously developed renal and hematopoietic failure. Because renal function was insufficient to support the conditioning regimen for HCT, we performed a deceased donor renal transplant in December 2012 prior to HCT with the known risk of graft-versus-graft rejection of the donor kidney. Seven months later he underwent allogeneic HCT. He obtained myeloid engraftment on day +11 and peripheral blood chimerism demonstrated all donor by day +21. He developed asymptomatic CMV reactivation and despite antirejection medications, mild skin graft-versus-host disease. He has maintained excellent renal function and remains transfusion independent with full hematopoietic recovery. He has not experienced any renal rejection episodes nor developed donor-specific antibodies toward his renal donor. Peripheral blood chimerism remains completely HCT donor. He is clinically well, now greater than two and a half yr after renal transplant and two yr after HCT. The continuing close collaboration between the Pediatric Nephrology and Bone Marrow Transplant teams is a major factor in this successful outcome.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.